NCT06994078Not yet recruiting
Clinical Application of PET Imaging Targeting Nectin-4 in Malignant Tumors
Source: ClinicalTrials.gov · Last updated 29 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study is a diagnostic study. Patients and healthy volunteers with clinically suspected or confirmed urothelial carcinoma, breast cancer, lung carcinoma and other malignant tumors with high expression of Nectin-4 will be recruited for PET/MR or PET/CT imaging targeting a Nectin-4-specific probe (in the case of \[68Ga\]Ga-NOTA-Nectin-4 antibody fragment) , to observe the reaction of volunteers and patients after injection of drugs, to evaluate the pharmacokinetics in vivo and the efficacy of diagnosis and staging, and to perform PET imaging in patients with contraindications. General information on the subjects' vital signs, clinical data, blood routine, liver and kidney functions and other biochemical indicators and other imaging data were collected, and histopathology of biopsy or surgical specimens was used as the final diagnostic criterion.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 56 (estimated)
- First submitted
- 20 May 2025
- Start date
- 1 Jul 2025
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Diseases
- Bladder cancer, Lung cancer
- NCT number
- NCT06994078
What you commit to
- Study type: Interventional
- Planned participants: 56
- From 1 Jul 2025 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- 4: Have a history of comorbid drug use;
Lab values
- 3: Patients with known hypersensitivity to Nectin-4 antibody fragment developers or synthetic excipients; fasting blood glucose level greater than 11.0 mmol/L prior to 18F-FDG injection；
Other
- All subjects who meet any of the exclusion criteria baseline will be excluded from the study:
- 1: Those who are unable to complete a PET/MR or PET/CT examination (including inability to lie down, claustrophobia, radiophobia, etc.);
- 2: Having other comorbidities;
- 5: Patients considered by the investigator to have poor compliance;
- 6: Patients during pregnancy or lactation;
- 7: Persons with other factors that make participation in this test inappropriate.
Who the study is looking for
- Each subject must meet all enrollment criteria to be eligible to participate in the study:
- 1: The subject or his/her legal representative is able to sign and date the informed consent form;
- 2: A commitment to comply with the research procedures and to cooperate in the implementation of the full research process;
- 3: Adult patients or healthy volunteers (aged 18 or above) of either sex;
- 4: Patients with clinically suspected or confirmed malignant tumors such as urothelial carcinoma, breast cancer and lung carcinoma (supporting evidence includes serum-related tumor markers, imaging data such as ultrasound, CT, MRI, etc., and histological pathology examination, etc.) and in good general condition;
- 5: Consistent with the results of specific laboratory tests;
- 6: Females of childbearing potential who have been using contraception for at least one month prior to screening and who are committed to using contraception for the entire study period and until a specified time after the end of the study；
- 7: Other set entry criteria.
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Coordinator of this site? Confirm its status | Wuhan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.